BeyondSpring Inc

BYSINASDAQ · USD
0.75USD0.00 (+5.79%)
112

BeyondSpring Inc (BYSI) Covered Calls

No qualifying covered call setups were found for BYSI in the prior session.

Read more

Running BYSI covered calls helps you generate consistent income from BeyondSpring Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on BeyondSpring Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best BYSI covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if BYSI stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling BYSI covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given BeyondSpring Inc covered call is worth writing.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Income-focused investors, long-term BYSI holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling BYSI covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best BeyondSpring Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile74.60% Elevated
  • Market cap (M$)31
  • 52 weeks high-69.26%
  • 52 weeks low31.58%
  • Analyst recommendationBuy
    2.00
  • Target price$1.25
    66.67% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-12
  • P/E
  • Future P/E
  • EPS (ttm)-0.16
  • EPS growth next 5 years

As of September 18, 2026

No illustrative rows to display.

As of September 18, 2026

Sell covered calls with the data behind you

Find the best BYSI covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial